KR102013801B1 - Ｈｐｖ 키메라 입자 - Google Patents

Ｈｐｖ 키메라 입자 Download PDF

Info

Publication number
KR102013801B1
KR102013801B1 KR1020147010686A KR20147010686A KR102013801B1 KR 102013801 B1 KR102013801 B1 KR 102013801B1 KR 1020147010686 A KR1020147010686 A KR 1020147010686A KR 20147010686 A KR20147010686 A KR 20147010686A KR 102013801 B1 KR102013801 B1 KR 102013801B1
Authority
KR
South Korea
Prior art keywords
hpv
chimeric
seq
polypeptide
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147010686A
Other languages
English (en)
Korean (ko)
Other versions
KR20140098061A (ko
Inventor
에드워드 피터 리비키
잉가 이사벨 힛제로쓰
Original Assignee
유니버시티 오브 케이프 타운
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 케이프 타운 filed Critical 유니버시티 오브 케이프 타운
Publication of KR20140098061A publication Critical patent/KR20140098061A/ko
Application granted granted Critical
Publication of KR102013801B1 publication Critical patent/KR102013801B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147010686A 2011-12-01 2012-12-03 Ｈｐｖ 키메라 입자 Expired - Fee Related KR102013801B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA2011/08841 2011-12-01
ZA201108841 2011-12-01
PCT/IB2012/056912 WO2013080187A1 (en) 2011-12-01 2012-12-03 Hpv chimaeric particle

Publications (2)

Publication Number Publication Date
KR20140098061A KR20140098061A (ko) 2014-08-07
KR102013801B1 true KR102013801B1 (ko) 2019-08-23

Family

ID=48534756

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147010686A Expired - Fee Related KR102013801B1 (ko) 2011-12-01 2012-12-03 Ｈｐｖ 키메라 입자

Country Status (18)

Country Link
US (1) US9771397B2 (enExample)
EP (1) EP2785842A4 (enExample)
JP (1) JP6228922B2 (enExample)
KR (1) KR102013801B1 (enExample)
CN (1) CN103890177B (enExample)
AU (1) AU2012345443B2 (enExample)
BR (1) BR112014012491A2 (enExample)
CA (1) CA2850293C (enExample)
HK (1) HK1198703A1 (enExample)
IL (1) IL232584B (enExample)
IN (1) IN2014DN03054A (enExample)
MX (1) MX355352B (enExample)
MY (1) MY184076A (enExample)
PH (1) PH12014500466A1 (enExample)
RU (1) RU2642287C2 (enExample)
SG (1) SG11201401579UA (enExample)
WO (1) WO2013080187A1 (enExample)
ZA (1) ZA201403557B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240122973A (ko) 2023-02-06 2024-08-13 영산대학교산학협력단 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
US9700639B2 (en) 2012-02-07 2017-07-11 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
MX385842B (es) * 2013-09-18 2025-03-18 Aura Biosciences Inc Conjugados de partículas de tipo virus y uso de las mismas.
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN105801704B (zh) * 2014-12-31 2020-06-02 艾托金生物医药（苏州）有限公司 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
EP3827846B1 (en) 2015-08-18 2024-10-02 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
CN114699525A (zh) 2015-08-18 2022-07-05 乐天医药生技股份有限公司 酞菁染料偶联物的制造方法及稳定偶联物
AU2016343722A1 (en) 2015-10-30 2018-05-24 Aleta Biotherapeutics, Inc. Targeted cancer therapy
BR112019020853A2 (pt) 2017-04-04 2020-05-12 Avidea Technologies, Inc. Vacinas à base de peptídeo, métodos de fabricação e usos das mesmas para induzir uma resposta imune
MX2019015769A (es) 2017-06-23 2020-08-03 Verimmune Inc Partículas tipo virus quiméricas y usos de estas como redireccionadores de respuestas inmunitarias específicos para el antígeno.
JP7641005B2 (ja) 2018-12-27 2025-03-06 ヴェリミューン インコーポレイテッド コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
CA3147849A1 (en) 2019-07-19 2021-01-28 Sinocelltech Ltd. Polyvalent immunogenicity composition for human papillomavirus
WO2021161179A1 (en) * 2020-02-10 2021-08-19 University Of Cape Town Plant produced bovine papillomavirus virus-like particles and pseudovirions
MX2023004465A (es) 2020-10-19 2023-06-19 Verimmune Inc Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077371A1 (en) * 2009-12-22 2011-06-30 University Of Cape Town Method for enhancing the expression of hpv l1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507657A (pt) * 1994-05-16 1997-09-09 Merck & Co Inc Proteina isolada e purificada de papilomavirus recombinante capsideos particulas semelhantes a virus processos a virus processos para produzir a proteina para tratar ou prevenir a infecçao por papilomavirus para produzir uma proteina de capsideo de papilomavirus recombinante montada em um capsideo ou particula semelhante a virus e para induzir uma resposta imune em um animal vertebrado composiçoes farmacêuticas kit para a detecçao de papilomavirus ou anticorpos para papilomavirus e sistema sinte
PL347472A1 (en) 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
PT1506222E (pt) 2002-05-17 2009-06-12 Univ Cape Town Proteínas l1 quiméricas do papilomavírus humano 16 incluindo um péptido l2, partículas semelhantes a vírus preparadas a partir daquelas e um método de preparação das partículas
WO2006119516A2 (en) 2005-04-29 2006-11-09 University Of Cape Town Expression of viral proteins in plants
CN102458440A (zh) * 2009-04-10 2012-05-16 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
AU2009348078B2 (en) 2009-06-19 2013-03-14 Eyegene Inc. Vaccine for cervical cancer
PE20120563A1 (es) 2009-06-25 2012-05-17 Glaxosmithkline Biolog Sa Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011077371A1 (en) * 2009-12-22 2011-06-30 University Of Cape Town Method for enhancing the expression of hpv l1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240122973A (ko) 2023-02-06 2024-08-13 영산대학교산학협력단 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템

Also Published As

Publication number Publication date
PH12014500466A1 (en) 2022-05-11
BR112014012491A2 (pt) 2017-06-06
EP2785842A4 (en) 2015-11-25
NZ622595A (en) 2016-04-29
IL232584B (en) 2018-10-31
MX355352B (es) 2018-04-17
US20140377367A1 (en) 2014-12-25
MY184076A (en) 2021-03-17
JP6228922B2 (ja) 2017-11-08
IN2014DN03054A (enExample) 2015-05-15
CN103890177B (zh) 2016-03-09
CA2850293A1 (en) 2013-06-06
JP2015500229A (ja) 2015-01-05
AU2012345443A1 (en) 2014-04-17
EP2785842A1 (en) 2014-10-08
RU2014126587A (ru) 2016-01-27
IL232584A0 (en) 2014-06-30
KR20140098061A (ko) 2014-08-07
RU2642287C2 (ru) 2018-01-24
AU2012345443B2 (en) 2017-10-26
CA2850293C (en) 2019-10-08
HK1198703A1 (en) 2015-05-29
US9771397B2 (en) 2017-09-26
WO2013080187A1 (en) 2013-06-06
MX2014006520A (es) 2014-11-21
CN103890177A (zh) 2014-06-25
SG11201401579UA (en) 2014-07-30
ZA201403557B (en) 2020-10-28

Similar Documents

Publication Publication Date Title
KR102013801B1 (ko) Ｈｐｖ 키메라 입자
Pineo et al. Immunogenic assessment of plant‐produced human papillomavirus type 16 L1/L2 chimaeras
CA2774640C (en) Virus like particles comprising target proteins fused to plant viral coat proteins
CA2855252C (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced in nicotiana tabacum
Franconi et al. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine
JP2017528137A (ja) 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン
Muthamilselvan et al. Assembly of human papillomavirus 16 L1 protein in Nicotiana benthamiana chloroplasts into highly immunogenic virus-like particles
CN102286104B (zh) Hpv6型l2n120e7e6融合蛋白基因、表达载体、方法、菌株和用途
WO2011077371A1 (en) Method for enhancing the expression of hpv l1
CN108503696B (zh) 一种酵母细胞表达的寨卡病毒亚单位疫苗
CN114106115A (zh) 一种腺病毒载体重组新冠病毒b.1.351变异株疫苗及其应用
CN116925195B (zh) 一种基于新型冠状病毒的mRNA疫苗
CN108503697B (zh) 一种果蝇细胞表达的寨卡病毒亚单位疫苗
CN112321718A (zh) 基于自组装铁蛋白纳米抗原颗粒、小反刍兽疫疫苗及其制备方法和应用
WO2023165435A1 (zh) 重组刺突蛋白及其制备方法和用途
CN110699366B (zh) 重组人乳头瘤病毒6和11亚型蛋白毕赤酵母表达
Song et al. Rice‐derived SARS‐CoV‐2 glycoprotein S1 subunit vaccine elicits humoral and cellular immune responses
NZ622595B2 (en) Hpv chimaeric particle
US20040161432A1 (en) Subunit vaccines and processes for the production thereof
RU2546240C1 (ru) РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 56
RU2546243C1 (ru) Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
Pineo Plant production and immunogenic characterisation of Human papillomavirus chimaeric vaccines
Castillo Esparza et al. Expression of the capsid protein of human papillomavirus in plants as an alternative for the production of vaccines.
Chabeda Immunogenic assessment of plant-produced Human papillomavirus type 16 chimaeric L1: L2 virus-like particles and the production of an encapsidated therapeutic DNA vaccine candidate
Pisuttinusart Development of plant-produced proteins for treatment and prevention against RSV type a (RSV-A)

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220820

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220820